Company Overview and News
PETALING JAYA: Several politically-linked stocks on Bursa Malaysia went on a wild ride yesterday, driven by the market volatility in the first day of trading post-14th general election (GE14).
THE recent action by the Inland Revenue Board (IRB) to squeeze more money out of SP Setia Bhd is all the more reason why companies and individuals have to be more careful with their books.
Tax returns: A file picture showing people submitting their tax forms at the Inland Revenue Board office in Penang. Companies in Malaysia are increasingly becoming fearful of the taxman.
PETALING JAYA: The Inland Revenue Board (IRB) has seized Country Heights Holdings Bhd’s (CHHB) executive chairman and major shareholder Tan Sri Lee Kim Yew’s fixed deposits placed with a foreign-owned bank amounting to RM126mil.
MarketWrap: Wall Street closed slightly lower on Thursday as bank shares declined in quiet holiday trading as traders looked to position for the new year. - Reuters The DJIA fell 13.14 points, or 0.07%, to 19,820.54, the S&P 500 lost 0.56 points, or 0.02%, to 2,249.36 and the Nasdaq dropped 6.47 points, or 0.12%, to 5,432.09. Forex summary *The ringgit gained 0.02% to 4.4843 per US$ *It was 1.04% lower at 4.
PETALING JAYA: Country Heights Holdings Bhd’s (CHHB) unit, Country Heights Sdn Bhd, which was ordered by the Shah Alam High Court to pay the Government tax arrears amounting to RM22.49mil, is appealing to the Finance Minister against the decision.
Tags / Keywords: Corporate News , Taxation , Country Heights Holdings Bhd , Inland Revenue Board
KUALA LUMPUR (Nov 28): The FBM KLCI is expected to trade higher today, in line with the firmer close at Wall Street and European markets last Friday, and move above the 1,630 level.
KUALA LUMPUR (Nov 25): Based on corporate announcements and news flow today, companies that may be in focus on Monday (Nov 28) could include the following: Sime Darby, TM, Ikhmas Jaya, Titijaya, Tune Protect, Country Heights, Chin Hin, Padini, Mega First and Kerjaya Prospek.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...